Clinical trials sponsored by ViiV Healthcare

Phase breakdown

Conditions studied

Recruiting trials led by ViiV Healthcare

• A Continued Access Study for Participants Transitioning From ViiV Healthcare-sponsored or ViiV Healthcare-collaborative Parent Studies for HIV Treatment
  NCT07393659 · Phase: Phase 3 · Ages: No age limits stated · Sex: All (male and female) · 4 locations
• A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
  NCT07202546 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 123 locations
• A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
  NCT06724640 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 2 locations
• A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
  NCT07650916 · Phase: Phase 3 · Ages: 12 Years and older · Sex: All (male and female) · 88 locations
• A Study to Investigate Cabotegravir for Neonates Exposed to HIV-1
  NCT07275606 · Phase: Phase 1, Phase 2 · Ages: Up to 10 Days · Sex: All (male and female) · 1 location
• A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
  NCT05418868 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants
  NCT07525544 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• First Time in Human Study of Long Acting VH4524184 Formulations
  NCT06310551 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 3 locations
• Mass Balance and Absolute Oral Bioavailability of [14C]VH4524184
  NCT07636928 · Phase: Phase 1 · Ages: 18 Years to 55 Years · Sex: All (male and female) · 1 location
• Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
  NCT05674656 · Phase: Phase 1, Phase 2 · Ages: 6 Years to 12 Years · Sex: All (male and female) · 8 locations

Common questions

How many trials is ViiV Healthcare recruiting for?

ViiV Healthcare is the lead sponsor of 10 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.